tiprankstipranks
Sage Therapeutics data ‘head-scratcher and inconclusive,’ says Citi
PremiumThe FlySage Therapeutics data ‘head-scratcher and inconclusive,’ says Citi
1M ago
Baird views Sage’s SURVEYOR as ‘failed phase 2a study’
PremiumThe Fly
Baird views Sage’s SURVEYOR as ‘failed phase 2a study’
1M ago
Sage Therapeutics- Phase 2 study in Huntington’s Disease meets primary endpoint
PremiumThe Fly
Sage Therapeutics- Phase 2 study in Huntington’s Disease meets primary endpoint
1M ago
Sage Therapeutics initiated with a Sell at Citi
PremiumThe FlySage Therapeutics initiated with a Sell at Citi
2M ago
Sage Therapeutics initiated with a Neutral at Baird
PremiumThe Fly
Sage Therapeutics initiated with a Neutral at Baird
2M ago
Sage CEO tells Bloomberg ‘lot of inbound interest’ on Huntington’s drug
PremiumThe Fly
Sage CEO tells Bloomberg ‘lot of inbound interest’ on Huntington’s drug
2M ago
Sage Therapeutics price target lowered to $18 from $20 at Mizuho
PremiumThe FlySage Therapeutics price target lowered to $18 from $20 at Mizuho
3M ago
Sage Therapeutics price target lowered to $18 from $22 at Truist
PremiumThe Fly
Sage Therapeutics price target lowered to $18 from $22 at Truist
3M ago
Sage Therapeutics price target lowered to $20 from $26 at Stifel
PremiumThe Fly
Sage Therapeutics price target lowered to $20 from $26 at Stifel
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100